---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088076"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T05:01:13.112168+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Apogee initiates dosing in Phase 1 trial of APG777 ahead of schedule for atopic dermatitis

## Summary
- First participants dosed in healthy-volunteer Phase 1 trial of APG777 ahead of initial timeline.
- APG777 is a novel half-life extended anti-IL-13 antibody for moderate-to-severe atopic dermatitis.
- Preclinical data suggest potential for dosing every two to three months, longer than existing therapies.
- Initial subcutaneous pharmacokinetic and safety data from healthy volunteers expected in mid-2024.
- Apogee plans to start a randomized Phase 2 trial in moderate-to-severe AD patients in 2024.

## SEC filing metadata
- accession: 0001104659-23-088076
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465923088076/0001104659-23-088076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465923088076/tm2322937d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088076
- JSON: https://secwatch.observer/filing/0001104659-23-088076.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.